Antiretrovirals

PDF / 169,913 Bytes
1 Pages / 595.245 x 841.846 pts (A4) Page_size
36 Downloads / 163 Views

1 S

Anaemia and viral rebound: 2 case reports In a retrospective cohort study involving 47 patients (study conducted between March 2009 and March 2019), two patients including a male patient [ages not stated; not all sexes stated] were described, who developed viral rebound following discontinuation of anti-retroviral therapy (ART) with zidovudine, tenofovir disoproxil fumarate, lamivudine, atazanavir/ritonavir, darunavir/ritonavir, raltegravir or maraviroc for neurosymptomatic cerebrospinal fluid HIV escape. Additionally, one of the two patients developed anaemia while receiving zidovudine [routes and dosages not stated; not all durations of treatments to reactions onsets and outcomes stated]. The patients, who had HIV-1 infection, had been receiving ART with tenofovir disoproxil fumarate, lamivudine and atazanavir/ ritonavir (1 patient), and lopinavir/ritonavir and raltegravir (1 patient). Following exhibition of neurosymptomatic cerebrospinal fluid HIV escape, one of the two patients’ ART was intensified by addition of zidovudine, and the other patient’s therapy was changed to zidovudine, lamivudine, darunavir/ritonavir, raltegravir and maraviroc. After 12 weeks, one of the two patients developed severe anaemia (Hb level

Data Loading...